Immatics (NASDAQ:IMTX) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Immatics (NASDAQ:IMTX) in a research note published on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $18.00 target price on the stock.

A number of other equities analysts have also recently weighed in on IMTX. Wall Street Zen raised shares of Immatics from a “sell” rating to a “hold” rating in a research report on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a research note on Thursday, January 22nd. Mizuho set a $25.00 price target on Immatics in a research report on Thursday, February 19th. Leerink Partners reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of Immatics in a research note on Thursday, December 4th. Finally, Guggenheim boosted their price objective on Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $19.00.

Immatics Price Performance

NASDAQ IMTX opened at $9.81 on Monday. The stock has a market capitalization of $1.32 billion, a P/E ratio of -5.33 and a beta of 1.34. The firm’s 50-day moving average is $9.84 and its two-hundred day moving average is $9.40. Immatics has a 12 month low of $3.30 and a 12 month high of $12.41.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.14. The business had revenue of $23.00 million during the quarter, compared to analysts’ expectations of $12.18 million. Immatics had a negative net margin of 411.90% and a negative return on equity of 41.81%. As a group, analysts anticipate that Immatics will post -0.72 EPS for the current year.

Institutional Investors Weigh In On Immatics

Several large investors have recently added to or reduced their stakes in IMTX. Bank of America Corp DE boosted its position in Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after buying an additional 2,231 shares during the period. Quarry LP purchased a new stake in shares of Immatics during the fourth quarter worth $84,000. Insigneo Advisory Services LLC purchased a new stake in shares of Immatics during the third quarter worth $103,000. Engineers Gate Manager LP acquired a new stake in shares of Immatics in the second quarter valued at $124,000. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Immatics in the fourth quarter valued at $129,000. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.